Article | May 9, 2017

What Pharma Is Doing To Triple Clinical Trial Successes

By Kristen Slawinski and Laura Moriarty

BiomarkerSearch

The typical success rate of a clinical trial is less than ten percent. While a single trial can cost upwards of $50 million, there is a strong sense of urgency to implement methods that reduce costs and increase a drug’s Likelihood of Approval (LOA).

Pharmaceutical companies are shifting to Electronic Data Capture (EDC), adopting earlier Phase II end-points, and even conducting trials in other countries in an effort to lower costs. Through early collaboration with regulatory agencies and use of Clinical Research Organizations (CROs), companies are also cutting trial timelines. Ultimately though, therapeutic efficacy and the safety of trial participants are the decisive factors for regulatory approval.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: